Coronavirus disease (COVID-19) is an infectious disease caused by the coronavirus SARS-CoV-2. Here we have collected APR news related to the COVID-19 pandemic, vaccination efforts and emerging treatments.
Monday, September 12, 2022
Pfizer Canada and BioNTech announced that Health Canada authorized COMIRNATY®, the companies' COVID-19 vaccine, as a three 3-µg primary series for children 6 months to less than 5 years of age.
read more
Monday, September 12, 2022
Vaxxinity, Inc. has initiated a rolling submission to the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom for conditional marketing authorization of its UB-612 COVID-...
read more
Wednesday, September 07, 2022
AstraZeneca’s Forxiga (dapagliflozin), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, is approved in China to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end...
read more
Tuesday, September 06, 2022
Novavax, announced that Swissmedic expanded its temporary authorization of Nuvaxovid™ (NVX-CoV2373) COVID-19 vaccine in Switzerland for adolescents aged 12 through 17 and as a heterologous and ...
read more
Tuesday, September 06, 2022
Novavax, Inc. announced that the European Commission (EC) has approved the expanded conditional marketing authorization (CMA) of Nuvaxovid™ (NVX-CoV2373) COVID-19 vaccine in the European Union (EU) as...
read more
Tuesday, September 06, 2022
Health Canada authorized an adapted version of the Moderna Spikevax COVID-19 vaccine. This vaccine (known as a "bivalent" vaccine) targets the original SARS-CoV-2 virus from 2019 and the Omicron (BA.1...
read more
Tuesday, September 06, 2022
Novavax, Inc. announced that Nuvaxovid™ (NVX-CoV2373) COVID-19 vaccine has been recommended for expanded conditional marketing authorization (CMA) in the European Union (EU) as a homologous and ...
read more
Friday, September 02, 2022
Pfizer and BioNTech announced a 30 µg booster dose of their Omicron BA.1- Bivalent COVID-19 Vaccine (COMIRNATY® Original/Omicron BA.1 15/15 µg) has been recommended for conditional marketing ...
read more
Wednesday, August 31, 2022
Pfizer and BioNTech announced that the FDA granted Emergency Use Authorization (EUA) of a 30-µg booster dose of the Pfizer-BioNTech COVID-19 vaccine, bivalent (Original [15 µg] and Omicron BA.4/BA.5 [...
read more
AstraZeneca's Evusheld (tixagevimab and cilgavimab, formerly AZD7442), a long-acting antibody combination, has been approved in Japan for both prevention (pre-exposure prophylaxis) and treatment of ...
read more
Novavax announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom (UK) has granted expanded conditional marketing authorization (CMA) for Nuvaxovid™ (NVX-...
read more
The FDA announced the removal of N95 respirators from the agency's medical device shortage list, signaling that demand or projected demand for this type of face protection device commonly used in ...
read more
Pfizer and BioNTech completed a submission to the European Medicines Agency (EMA) for the booster dose of an Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine for individuals 12 years of age and ...
read more
Wednesday, August 24, 2022
Pfizer and BioNTech updated efficacy results from a Phase 2/3 trial evaluating a three 3-µg dose series of the Pfizer-BioNTech COVID-19 Vaccine in children 6 months through 4 years of age, reinforcing...
read more
Wednesday, August 24, 2022
Valneva confirmed that the World Health Organization (WHO) issued recommendations for use of the their inactivated COVID-19 vaccine.
read more